What To Know
- , a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced it has completed the first evaluation time point for its proof of concept clinical trial for the treatment of cellulite.
- “Having led the clinical development of Cellfina, the only treatment with FDA clearance for producing long-term reduction of cellulite, I am particularly aware of the unmet need in the treatment of cellulite.
April 9, 2019
Soliton, Inc., a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced it has completed the first evaluation time point for its proof of concept clinical trial for the treatment of cellulite.
Soliton notes results for a single acoustic shockwave treatment are being assessed by a blinded group of clinicians.
The study, conducted by Dr. Michael Kaminer at SkinCare Physicians in Boston, MA, in collaboration with Dr. Elizabeth Tanzi of Capital Laser and Skin Care, concluded evaluation of safety and efficacy for all patients through the initial 12-week time point. The study is designed to evaluate results at both the 12-week and 26-week timepoints from initial treatment in order to assess both near-term and long-term effects.
Join our more than 200K fans here to follow the Company here.
“We are pleased with how quickly this trial has progressed,” commented Dr. Chris Capelli, Soliton’s President and CEO. “We look forward to disclosing the independent assessment of the data from this trial in the near future. We believe the opportunity in the treatment of cellulite could be very significant for Soliton.”
Dr. Michael Kaminer of SkinCare Physicians added: “Having led the clinical development of Cellfina, the only treatment with FDA clearance for producing long-term reduction of cellulite, I am particularly aware of the unmet need in the treatment of cellulite. Having a non-invasive alternative treatment could provide a real benefit for patients while also expanding the breadth of services offered by clinicians.”
Drs. Kaminer and Tanzi are members of Soliton’s Scientific Advisory Board.
